To view this email as a web page, click here.
 
Lack of insulin competition high priority for FDA
FDA fast-tracks biosimilar insulin products to elevate competition.
Read more
 
New oral drugs treat MS
FDA approved 2 new multiple sclerosis drugs. Here's what you should know about them.
Read more
 
The fight to end misleading info on biosimilars
From our sister brand, Managed Healthcare Executive: Industry groups are calling for clear FDA guidance on language used by biologic originators to protect market share.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.